Lemaignen Adrien, Ridel Christophe, Hertig Alexandre, Rondeau Eric
Urgences Néphrologiques et Transplantation Rénale, Hôpital Tenon, Assistance Publique des Hôpitaux de Paris, 4, rue de la Chine, 75020 Paris, France.
Nephrol Ther. 2013 Jun;9(3):129-36. doi: 10.1016/j.nephro.2012.10.011. Epub 2012 Dec 21.
Hemolytic and uremic syndrome (HUS) is the most feared complication of infections with enterohemorrhagic Escherichia coli. During summer 2011, Europe was the scene of a large outbreak of shiga-toxin producing E. coli gastroenteritis, occasioning more than 800 cases of HUS, highlighting this public health problem. Last years, many advances have occurred, on the physiopathology, microbiology or therapeutics. We review here these different aspects, from molecular identification of the German bacteria, to the use of targeted therapies as eculizumab in severe forms, or even the major role of complement activation in the physiopathology of HUS.
溶血尿毒综合征（HUS）是肠出血性大肠杆菌感染最可怕的并发症。2011年夏季，欧洲爆发了大规模产志贺毒素大肠杆菌胃肠炎疫情，导致800多例溶血尿毒综合征病例，凸显了这一公共卫生问题。近年来，在生理病理学、微生物学或治疗学方面取得了许多进展。我们在此回顾这些不同方面，从德国细菌的分子鉴定，到在严重病例中使用依库珠单抗等靶向治疗，甚至补体激活在溶血尿毒综合征生理病理学中的主要作用。
